CCSVI

Anne Kingston on the MS research that captured headlines in 2013

Scanning study finds narrowed veins common, CCSVI rare

Last week’s shut-down of the Albany, NY clinical trial investigating CCSVI treatment due to lack of patient enrollment is a big set-back on a number of fronts. It’s bad news for the Saskatchewan government, which allocated $2.2 million and recruited patients to travel to the U.S.—and a  blow for those who’d taken part in the trial or were lined up to go. But, like all failures, it’s instructive.

Anne Kingston explains why we’ve reached the WTF moment in CCSVI research

On the quest for clarity on MS theory

OTTAWA – The Conservatives have used their Senate majority to kill legislation that would have authorized a national strategy to deal with a controversial therapy for multiple sclerosis.

The third in a series on the credibility of health information on the Web

TORONTO – The federal government is going ahead with a patient trial of a controversial experimental treatment for multiple sclerosis.

A defeated private member’s bill shows how pitched the battle has become

Brad Wall: ‘It’s a good day in the province of Saskatchewan’

MS drugs get fast-tracked all the time. Why can’t a clinical trial get the same treatment?

Zamboni’s research almost certainly has to have been junk